Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01599793
Other study ID # 12-1031
Secondary ID NCI-2012-00677
Status Completed
Phase Phase 2
First received
Last updated
Start date May 2012
Est. completion date December 2018

Study information

Verified date March 2020
Source University of Chicago
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is being done to help researchers understand more about prostate cancer that has spread to the bones by using the newest magnetic resonance imaging (MRI) techniques and to better understand the effect of an experimental drug called XL184 (or cabozantinib) on bone disease. The other purposes of the study are to better understand the effect of XL184 on prostate cancer progression, bone pain, and on any cancer cells that patients may have circulating within the blood (called circulating tumor cells)


Description:

PRIMARY OBJECTIVES:

I. To determine effect of XL184 on the functional MRI metrics Ktrans and apparent diffusion coefficient (ADC) within castrate resistant prostate cancer bone metastases.

SECONDARY OBJECTIVES:

I. To quantify progression free survival in men with castrate resistant prostate cancer (CRPC) treated with XL184 according to Prostate Cancer Working Group criteria.

II. To correlate and changes in MRI based functional metrics with bone scan, prostate specific antigen (PSA), Response Evaluation Criteria in Solid Tumors (RECIST) response criteria, circulating tumor cells (CTC) number and with changes in pain.

III. To explore c-MET, phospho-c-MET staining on circulating tumor cells as a predictive biomarker for response and duration of response to XL-184.

OUTLINE:

Patients receive cabozantinib orally (PO) once daily (QD). Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date December 2018
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed prostate cancer with progressive disease

- Evidence of castration resistance defined as disease progression despite a testosterone level < 50ng/dL (or surgical castration)

- Evidence of metastatic disease to the bones within the lumbar spine, sacrum, or pelvic bones that is identifiable on screening pelvic MRI

- If patient has had prior pelvis radiation therapy (RT), then bone metastases must be out of radiated port (e.g. lumbar or sacral spine)

- Any prior therapy for castrate disease acceptable other than prior XL184 with a minimum washout of 28 days for any other anticancer therapy

- Patients with castrate resistant disease post antiandrogen therapy/withdrawal must meet at least one of the following criteria:

- Have not received docetaxel chemotherapy

- Have received docetaxel chemotherapy but received less then 225mg/m2 cumulative dose

- Have documented liver metastases

- Have no pain or pain that does not require a long acting (SR) narcotic

- Have received mitoxantrone chemotherapy in the past for CRPC

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study

- Patients who are receiving any other investigational agents

- Prior treatment with other vascular endothelial growth factor (VEGF) or c-MET targeted therapies

- History of hematemesis or hemoptysis

- The subject has uncontrolled or significant intercurrent illness

- The patient requires concomitant treatment, in therapeutic doses, with anticoagulants

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
cabozantinib
Given PO
Other:
laboratory biomarker analysis
Correlative studies
Procedure:
magnetic resonance imaging
Undergo MRI

Locations

Country Name City State
United States University of Chicago Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
University of Chicago NorthShore University HealthSystem

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the Functional MRI Metrics Ktrans Between 2 Weeks and Baseline Ktrans is a measurement calculating the volume transfer constant of the contrast reagent and essentially is a measurement of vascular perfusion.
To determine the effect of XL184 on the functional MRI metrics Ktrans, Ktrans parameters were measured at baseline, two week time-point, 12 weeks, and 24 weeks for disease monitoring. Change between baseline and 2 weeks reported.
baseline, 2 weeks
Secondary Association of Progression Free Survival (PFS) With Ktrans and ADC Time to progression or progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
The approximate survival after standard therapies in this setting is bleak and in the order of months.
Too few events for a meaningful statistical analysis; no significant results were obtained in Cox regression analyses.
Therefore, we calculated the median PFS time and its 95% confidence interval.
From start of treatment to time of progression or death, whichever occurs first, assessed up to 1 year
Secondary Changes in Bone Scan Response Bone Scan Response at weeks 2, 12, and 24 were collected. Change between baseline and 2 weeks are reported Bone Scan Response were measured as increase, decrease, or stable of bone lesions and scored as 1, -1, or 0, respectively, where higher values represent a worse outcome. baseline, 2 weeks
Secondary Correlation of Percent Change in the Functional MRI Metrics to RECIST Tumor Measurements The protocol proposed to collect RECIST tumor measurements at weeks 0, 12, and 24.
However, the data were not collected
baseline, 12 weeks, and 24 weeks
Secondary Change of PSA Between 12 Weeks and Baseline PSA at weeks 0, 12, and 24 were collected. Change between baseline and 12 weeks are reported baseline, 12 weeks
Secondary Correlation of Percent Change in the Functional MRI Metrics With CTC The protocol proposed to collect CTC measurements at weeks 0, 12, and 24. However, the data were not collected baseline, 12 weeks, and 24 weeks
Secondary Change in Pain Scale Between 12 Weeks and Baseline Pain scores are measured at baseline and weeks 12, and 24. Change between baseline and 12 weeks are reported .
In the pain score ranged from 0 to 10. 10 denotes most pain.
baseline,12 weeks
See also
  Status Clinical Trial Phase
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Active, not recruiting NCT01996046 - FDG PET/CT in Breast Cancer Bone Mets
Completed NCT01358539 - Palliation: the Effect of Education on Pain Phase 3
Terminated NCT00981578 - ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain N/A
Terminated NCT00757757 - A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases Phase 1/Phase 2
Completed NCT00762346 - Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Phase 4
Completed NCT00420433 - Bone Response in Metastatic Breast Cancer Involving Bones N/A
Completed NCT02826382 - Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041 Early Phase 1
Terminated NCT05301062 - A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
Recruiting NCT06367491 - National Database of Bone Metastases
Completed NCT03223727 - Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
Completed NCT00830180 - Open Label Extension In Cancer Patients Phase 2
Active, not recruiting NCT03305224 - The Combination Therapy With Ra-223 and Enzalutamide Phase 2
Withdrawn NCT04109937 - External Beam Radiation Therapy Post Surgery in Patients With Lower Extremity Bone Metastases Randomized Efficacy Trial N/A
Active, not recruiting NCT02880943 - Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL) Phase 1/Phase 2
Completed NCT01696760 - Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology N/A
Completed NCT00958477 - A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer Phase 1
Completed NCT03979118 - Exercise Prescription in Patients With Bone Metastases
Completed NCT03353090 - Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients N/A
Recruiting NCT05167669 - Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU Early Phase 1